Combination therapy for MDS
AssigneeChildren's Hospital Medical Center
InventorsDaniel Starczynowski, Garrett W. Rhyasen
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.
Claims29
A method of treating myelodysplastic syndrome (MDS) in an individual having an MDS characterized by increased IRAK1 activation, comprising the step of administering to said individual a composition comprising an IRAK1/4 inhibitor.
A method of treating myelodysplastic syndrome or acute myeloid leukemia in an individual, wherein said myelodysplastic syndrome or said acute myeloid leukemia is characterized by increased IRAK1 activation, comprising the step of administering to said individual
- a) an IRAK1/4 inhibitor;
- and
- b) an agent selected from an apoptotic agent, an immune modulating agent, an epigenetic modifying agent, and combinations thereof.
Dependencies are inferred from the claim text.